Publicaciones Imprimir Ong SY, Chen L, Manzano JM, Merryman R, Shah H, Stuver R, Desai SH, LaCasce A, Falade A, Baron K, Ganesan N, Chang T, Durani U, Othman T, Armand P, Mei M, Moskowitz AJ, Herrera AF. Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin. Blood Cancer J. 2026 Jun 25 Epub 2026 June 25 View PubMed Falade AS, Redd R, Desai SH, Moskowitz AJ, Shah H, Geyer SM, Ganesan N, Chang T, Othman T, Shah GL, Nedved A, Durani U, Ng LS, Baron K, Ong SY, Yoon K, Ansell SM, Iyengar S, Micallef I, Stuver R, Herrera AF, Mei M, Armand P, Merryman RW. Impact of novel therapies on the efficacy of posttransplantation brentuximab vedotin maintenance in Hodgkin lymphoma. Blood Adv. 2026 Jun 9; 10 (11):3833-3844 View PubMed Paczkowska J, Tang M, Wright KT, Song L, Luu K, Shanmugam V, Welsh EL, Weirather JL, Besson N, Olszewski H, Porter BA, Pfaff KL, Redd RA, Cader FZ, Mandato E, Ouyang J, Calabretta E, Bai G, Lawton LN, Armand P, Rodig SJ, Liu XS, Shipp MA. Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma. Nat Commun. 2024 Dec 30; 15 (1):10740 View PubMed Ryan CE, Zon RL, Redd R, Fisher DC, Shouval R, Kumar A, Crombie JL, Sadrzadeh H, Kim AI, Nayak L, Chukwueke UN, Jacobson CA, Frigault MJ, Palomba ML, Armand P, Epstein-Peterson Z, Merryman RW. Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement. Br J Haematol. 2023 Dec; 203 (5):774-780 Epub 2023 Aug 16 View PubMed Olszewski AJ, Phillips TJ, Hoffmann MS, Armand P, Kim TM, Yoon DH, Mehta A, Greil R, Westin J, Lossos IS, Munoz JL, Sit J, Wei MC, Yang A, Chen V, Purev E, Yee DL, Jaeger U. Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study. Blood Adv. 2023 Oct 24; 7 (20):6055-6065 View PubMed Gadi D, Martindale SP, Chiu PY, Khalsa J, Chen PH, Fernandes SM, Wang Z, Tyekucheva S, Machado JH, Fisher DC, Armand P, Davids MS, Rodig S, Sherry B, Brown JR. Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kdelta inhibitors. Blood Cancer J. 2023 Feb 2; 13 (1):22 Epub 2023 Feb 02 View PubMed Gadi D, Griffith A, Tyekucheva S, Wang Z, Rai V, Vartanov A, Thrash E, Fernandes SM, Lehmberg TZ, Lee B, Martindale SP, Machado JH, Odejide O, Armand P, Fisher DC, Arnason J, Davids MS, Lederer JA, Brown JR. A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. Leukemia. 2022 Mar; 36 (3):723-732 Epub 2021 Nov 06 View PubMed Moahi K, Ralefala T, Nkele I, Triedman S, Sohani A, Musimar Z, Efstathiou J, Armand P, Lockman S, Dryden-Peterson S. HIV and Hodgkin Lymphoma Survival: A Prospective Study in Botswana. JCO Glob Oncol. 2022 Jan; 8:e2100163 View PubMed Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R, Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL, Carlo-Stella C. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 Sep; 35(9):2672-2683. Epub 2021 Mar 03. View PubMed Kekre N, Kim HT, Hofer J, Ho VT, Koreth J, Armand P, Nikiforow S, Gooptu M, Romee R, Alyea EP, Nageshwar P, Glotzbecker B, El-Jawahri A, DeFilipp Z, Soiffer RJ, Antin JH, Chen YB, Cutler C. Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 May; 56 (5):1217 View PubMed Kekre N, Kim HT, Hofer J, Ho VT, Koreth J, Armand P, Nikiforow S, Gooptu M, Romee R, Alyea EP, Nageshwar P, Glotzbecker B, El-Jawahri A, DeFilipp Z, Soiffer RJ, Antin JH, Chen YB, Cutler C. Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 May; 56 (5):1006-1012 Epub 2020 Sept 08 View PubMed Armand P, Lesokhin A, Borrello I, Timmerman J, Gutierrez M, Zhu L, Popa McKiver M, Ansell SM. A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. Leukemia. 2021 Mar; 35 (3):777-786 Epub 2020 June 29 View PubMed Crombie JL, Armand P. Diffuse Large B-Cell Lymphoma's New Genomics: The Bridge and the Chasm. J Clin Oncol. 2020 Oct 20; 38 (30):3565-3574 Epub 2020 Aug 19 View PubMed Carreau NA, Armand P, Merryman RW, Advani RH, Spinner MA, Herrera AF, Ramchandren R, Hamid MS, Assouline S, Santiago R, Wagner-Johnston N, Paul S, Svoboda J, Bair SM, Barta SK, Nathan S, Karmali R, Torka P, David K, Lansigan F, Persky D, Godfrey J, Chavez JC, Xia Y, Diefenbach C. Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. Br J Haematol. 2020 Oct; 191(1):44-51. Epub 2020 May 19. View PubMed Cader FZ, Hu X, Goh WL, Wienand K, Ouyang J, Mandato E, Redd R, Lawton LN, Chen PH, Weirather JL, Schackmann RCJ, Li B, Ma W, Armand P, Rodig SJ, Neuberg D, Liu XS, Shipp MA. A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nat Med. 2020 Sep; 26 (9):1468-1479 Epub 2020 Aug 10 View PubMed Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017 Jul 13; 130 (2):221-228 Epub 2017 May 03 View PubMed PST-20606410 Inicio Publicaciones